Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234532 · ClinicalTrials.gov registry record · Phase 2
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01234532: Clinical Trial Phase 2 study, sponsored by University of Maryland, Baltimore.
NCT01234532 is a Phase 2 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01234532, a Phase 2 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving entinostat and anastrozole together works in treating postmenopausal women with triple-negative breast cancer that can be removed by surgery. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving entinostat together with anastrozole may be an effective treatment for breast cancer.
Primary Outcome
Since the study was terminated early there was insufficient data for analysis and to recommend a phase II dose of entinostat in combination with anastrozole
Interventions
- PROCEDURE therapeutic conventional surgery
- DRUG anastrozole
- OTHER diagnostic laboratory biomarker analysis
- DRUG entinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-10 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
Why NCT01234532 stopped before completion
NCT01234532 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which therapeutic conventional surgery is the first listed.
NCT01234532 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01234532 about?
NCT01234532 is a clinical study titled "Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery". This phase II trial is studying how well giving entinostat and anastrozole together works in treating postmenopausal women with triple-negative breast cancer that can be removed by surgery. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen...
What is the current status of trial NCT01234532?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2010-10. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01234532?
The interventions under investigation include: therapeutic conventional surgery (PROCEDURE), anastrozole (DRUG), diagnostic laboratory biomarker analysis (OTHER), entinostat (DRUG).
Who is sponsoring clinical trial NCT01234532?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01234532's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia